JP2012525398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525398A5 JP2012525398A5 JP2012508607A JP2012508607A JP2012525398A5 JP 2012525398 A5 JP2012525398 A5 JP 2012525398A5 JP 2012508607 A JP2012508607 A JP 2012508607A JP 2012508607 A JP2012508607 A JP 2012508607A JP 2012525398 A5 JP2012525398 A5 JP 2012525398A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- ophthalmic
- tocotrienol
- alpha
- vision
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 117
- 208000035475 disorder Diseases 0.000 claims description 100
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 80
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 80
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 80
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 74
- 201000004569 Blindness Diseases 0.000 claims description 71
- 238000009472 formulation Methods 0.000 claims description 71
- 230000004393 visual impairment Effects 0.000 claims description 71
- 229940064063 alpha tocotrienol Drugs 0.000 claims description 60
- 239000011730 α-tocotrienol Substances 0.000 claims description 60
- 235000019145 α-tocotrienol Nutrition 0.000 claims description 60
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 56
- 208000018769 loss of vision Diseases 0.000 claims description 36
- 231100000864 loss of vision Toxicity 0.000 claims description 36
- 230000000750 progressive effect Effects 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 35
- 150000002148 esters Chemical class 0.000 claims description 34
- 208000014674 injury Diseases 0.000 claims description 34
- 208000002780 macular degeneration Diseases 0.000 claims description 34
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 32
- 230000007812 deficiency Effects 0.000 claims description 30
- 208000011580 syndromic disease Diseases 0.000 claims description 30
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 28
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 28
- 230000001684 chronic effect Effects 0.000 claims description 28
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 28
- 208000018737 Parkinson disease Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 229930003802 tocotrienol Natural products 0.000 claims description 25
- 239000011731 tocotrienol Substances 0.000 claims description 25
- 235000019148 tocotrienols Nutrition 0.000 claims description 25
- 102000014461 Ataxins Human genes 0.000 claims description 24
- 108010078286 Ataxins Proteins 0.000 claims description 24
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 24
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 24
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 24
- 208000012268 mitochondrial disease Diseases 0.000 claims description 24
- 230000008733 trauma Effects 0.000 claims description 24
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 23
- 208000014644 Brain disease Diseases 0.000 claims description 22
- 208000032274 Encephalopathy Diseases 0.000 claims description 22
- 230000006378 damage Effects 0.000 claims description 22
- 208000017442 Retinal disease Diseases 0.000 claims description 20
- 230000004770 neurodegeneration Effects 0.000 claims description 19
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 19
- 208000010412 Glaucoma Diseases 0.000 claims description 18
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 18
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 18
- 230000000699 topical effect Effects 0.000 claims description 17
- 208000027073 Stargardt disease Diseases 0.000 claims description 16
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 16
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 206010033799 Paralysis Diseases 0.000 claims description 15
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 15
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 14
- 208000030768 Optic nerve injury Diseases 0.000 claims description 14
- 206010038923 Retinopathy Diseases 0.000 claims description 14
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 14
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 14
- 239000011722 γ-tocotrienol Substances 0.000 claims description 14
- 235000019150 γ-tocotrienol Nutrition 0.000 claims description 14
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 14
- 239000011729 δ-tocotrienol Substances 0.000 claims description 14
- 235000019144 δ-tocotrienol Nutrition 0.000 claims description 14
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 14
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 13
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 13
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 13
- 239000011723 β-tocotrienol Substances 0.000 claims description 13
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 13
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 13
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 12
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 12
- 239000003732 agents acting on the eye Substances 0.000 claims description 12
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 12
- 208000006443 lactic acidosis Diseases 0.000 claims description 12
- 229940125702 ophthalmic agent Drugs 0.000 claims description 12
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 10
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 10
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 10
- 208000028226 Krabbe disease Diseases 0.000 claims description 10
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 10
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 10
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 10
- 206010030113 Oedema Diseases 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 10
- 206010034010 Parkinsonism Diseases 0.000 claims description 10
- 208000001749 optic atrophy Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 230000009286 beneficial effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 230000000642 iatrogenic effect Effects 0.000 claims description 7
- 238000002647 laser therapy Methods 0.000 claims description 7
- 238000002428 photodynamic therapy Methods 0.000 claims description 7
- 238000011476 stem cell transplantation Methods 0.000 claims description 7
- 102000007371 Ataxin-3 Human genes 0.000 claims description 6
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 6
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 6
- 206010057410 Hippus Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000006136 Leigh Disease Diseases 0.000 claims description 6
- 208000017507 Leigh syndrome Diseases 0.000 claims description 6
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 6
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- -1 alpha-tocotrienol ester Chemical class 0.000 claims description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 208000035965 Postoperative Complications Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 4
- 229940113601 irrigation solution Drugs 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 3
- 150000003612 tocotrienol derivatives Polymers 0.000 claims description 2
- 150000003773 α-tocotrienols Polymers 0.000 claims description 2
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims 26
- 238000002560 therapeutic procedure Methods 0.000 claims 13
- 229940012356 eye drops Drugs 0.000 claims 3
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 230000002262 irrigation Effects 0.000 claims 2
- 238000003973 irrigation Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 210000003205 muscle Anatomy 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 208000021090 palsy Diseases 0.000 description 9
- 208000032253 retinal ischemia Diseases 0.000 description 4
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21476009P | 2009-04-28 | 2009-04-28 | |
| US61/214,760 | 2009-04-28 | ||
| PCT/US2010/032622 WO2010126910A1 (en) | 2009-04-28 | 2010-04-27 | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525398A JP2012525398A (ja) | 2012-10-22 |
| JP2012525398A5 true JP2012525398A5 (enExample) | 2013-06-13 |
Family
ID=43032521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508607A Pending JP2012525398A (ja) | 2009-04-28 | 2010-04-27 | 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120136048A1 (enExample) |
| EP (1) | EP2424360A4 (enExample) |
| JP (1) | JP2012525398A (enExample) |
| BR (1) | BRPI1015006A2 (enExample) |
| CA (1) | CA2760357A1 (enExample) |
| WO (1) | WO2010126910A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470798B2 (en) | 2003-09-19 | 2008-12-30 | Edison Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| EP2564843B1 (en) * | 2005-06-01 | 2018-12-26 | Bioelectron Technology Corporation | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| DK2220030T3 (en) | 2007-11-06 | 2016-04-11 | Edison Pharmaceuticals Inc | 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial |
| EP2237664A4 (en) * | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| EP2262508B1 (en) | 2008-03-05 | 2018-10-03 | BioElectron Technology Corporation | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| CA2729227C (en) | 2008-06-25 | 2018-05-22 | Andrew W. Hinman | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| HUE037592T2 (hu) * | 2009-08-26 | 2018-09-28 | Bioelectron Tech Corp | Eljárások cerebrális ischemia megelõzésére és kezelésére |
| BR112013029577B1 (pt) * | 2011-05-18 | 2021-03-09 | Malaysian Palm Oil Board | uso de composições compreendendo extratos ou materiais derivados de licor vegetal de óleo de palma para a inibição de perda de visão devido a angiogênese |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| PL3233786T3 (pl) | 2014-12-16 | 2022-06-13 | Ptc Therapeutics, Inc. | Polimorficzne i amorficzne postacie (r)-2-hydroksy-2-metylo-4-(2,4,5-trimetylo-3,6-dioksocykloheksa-1,4-dienylo)butanoamidu |
| EP3390377A1 (en) | 2015-12-16 | 2018-10-24 | BioElectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US20190365705A1 (en) * | 2017-01-20 | 2019-12-05 | Ohio State Innovation Foundation | Topical tocotrienol compositions and methods of increasing skin stem cells |
| BR112021007153A2 (pt) | 2018-10-17 | 2021-07-20 | Ptc Therapeutics, Inc. | 2,3,5-trimetil-6-nonilcicloexa-2,5-dieno-1,4-diona para a supressão e tratamento de a-sinucleinopatias, tauopatias e outros distúrbios |
| EP3981397A1 (en) | 2020-10-08 | 2022-04-13 | Global Scientific | Tocotrienols derivates, methods and uses thereof |
| WO2023283466A1 (en) | 2021-07-08 | 2023-01-12 | Ptc Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217992A (en) * | 1989-10-04 | 1993-06-08 | Bristol-Myers Squibb Company | Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders |
| JPH09157165A (ja) * | 1995-12-11 | 1997-06-17 | Lion Corp | 点眼薬及び白内障の遅延・治療用剤 |
| JPH10109934A (ja) * | 1996-10-04 | 1998-04-28 | Sekisui Chem Co Ltd | 炎症性眼疾患用剤 |
| JP4447198B2 (ja) * | 2001-02-08 | 2010-04-07 | 富士化学工業株式会社 | トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物 |
| US20060127505A1 (en) * | 2002-01-16 | 2006-06-15 | David Haines | Anti-inflammatory formulations |
| US20040034093A1 (en) * | 2002-05-30 | 2004-02-19 | Hensley Kenneth L. | Methods for enhancing motor performance and/or endurance |
| JP2004323486A (ja) * | 2003-04-30 | 2004-11-18 | National Institute Of Advanced Industrial & Technology | 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬 |
| US7470798B2 (en) * | 2003-09-19 | 2008-12-30 | Edison Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| ES2532997T3 (es) * | 2005-04-22 | 2015-04-06 | Elizabeth Stuart | Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia |
| US20070092502A1 (en) * | 2005-09-01 | 2007-04-26 | Allergan, Inc. | Method of Treating Glaucoma |
| EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| CN102238949A (zh) * | 2008-10-09 | 2011-11-09 | 拉姆斯科股份有限公司 | 治疗干眼综合征的组合物和方法 |
-
2010
- 2010-04-27 WO PCT/US2010/032622 patent/WO2010126910A1/en not_active Ceased
- 2010-04-27 JP JP2012508607A patent/JP2012525398A/ja active Pending
- 2010-04-27 CA CA2760357A patent/CA2760357A1/en not_active Abandoned
- 2010-04-27 BR BRPI1015006A patent/BRPI1015006A2/pt not_active IP Right Cessation
- 2010-04-27 US US13/266,240 patent/US20120136048A1/en not_active Abandoned
- 2010-04-27 EP EP10770214A patent/EP2424360A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525398A5 (enExample) | ||
| JP2012525397A5 (enExample) | ||
| US20120136048A1 (en) | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases | |
| DE69423782T2 (de) | Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck | |
| JP5959507B2 (ja) | 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン | |
| JP2017193594A (ja) | 眼科疾患を治療するためのトコトリエノールキノンの製剤 | |
| SI2424495T1 (en) | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones | |
| JP2012525399A5 (enExample) | ||
| US10335367B2 (en) | Use of selected anticholinergic zwitterions | |
| JP2023179418A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| US20130102679A1 (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
| WO2018074421A1 (ja) | 眼科用剤及び眼科用薬 | |
| JP2009519962A5 (enExample) | ||
| Qamar et al. | Supratarsal injection of triamcinolone for vernal keratoconjunctivitis | |
| CN116350790B (zh) | 组合物及其在制备用于治疗老花眼的药物中的用途 | |
| Guan et al. | Potential Application of Bendazac L-Lysine for Controlling Myopia Progression, as Demonstrated in Two Experimental Guinea Pig Myopia Models | |
| KR20110025824A (ko) | 조절성 눈피로의 예방 또는 치료용 화합물 | |
| WO2007038549B1 (en) | Treatment of inflammation and vascular abnormalities of the eye | |
| WO1996010403A1 (en) | Use of retinoid glycosides in topical pharmaceutical compositions | |
| Nowroozzadeh | Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis | |
| Apel | A child with itchy eyes | |
| WO2017075019A1 (en) | Eye drops | |
| IT202100005777A1 (it) | Composizione per l’uso nel trattamento dell’occhio secco | |
| SUGAR | Ocular side effects of systemic therapy of cutaneous diseases | |
| Garrigue et al. | A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models |